

In the Claims:

1. (currently amended) A method of screening a human subject in need of treatment for a solid epithelial tumor that overexpresses ErbB2, as an aid in selecting between therapy with Trastuzumab alone and Trastuzumab combined with GW572016, comprising determining whether the tumor expresses p95^{ErbB2}, where expression of p95^{ErbB2} indicates said subject is more likely to exhibit a favorable clinical response to treatment that includes GW572016 in combination with trastuzumab, than to treatment with trastuzumab alone ~~that does not include GW572016~~.
2. (original) A method according to claim 1 where expression of p95^{ErbB2} in tumor tissue is assessed by immunohistochemical methods.
3. (original) A method according to claim 1 where expression of p95^{ErbB2} is assessed by measuring ErbB2 extracellular domain (ECD) in the subject's serum.
4. -5. (canceled).
6. (original) A method according to claim 1 where said tumor is selected from breast, ovarian, colon, head and neck, bladder, renal cell and lung tumors.
7. (original) A method according to claim 1 where said subject has breast cancer.
8. (canceled).
9. (original) A method according to claim 1 where said subject has previously been treated with trastuzumab.
10. - 28. (canceled).